A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
Status:
Not yet recruiting
Trial end date:
2024-10-23
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide
(LY3298176) in pediatric participants with obesity. The blood tests will be performed to
investigate how the body processes the study drug in these participants. For each
participant, the study will last about approximately 11 weeks excluding the screening period.